walczak j. , pawlik d. , jasińska a. , garbacka m ... j. , pawlik d. , jasińska a. , garbacka m.....
Post on 12-Jul-2018
223 Views
Preview:
TRANSCRIPT
Mean change in HbA_1c [%]
-0,37%
-0,42%
-1,53%
-0,22%
-0,42%
-1,67%
-2,00% -1,00% 0,00%
type 1
type 2 basal-bolus
type 2 insulin+OAD
IDet NPH
Mean change in BMI [kg/m2]
-0,2
0,26
0,42
0,06
0,51
0,99
type 1
type 2 basal-
bolus
type 2
insulin+OAD
IDet NPH
Non-specificmortality
No
Yes
No
Yes
Lasertreatment
ACEI
treatment
Statin
treatment
Aspirin
treatment
User sets simulation conditions
Generate baseline population
Any patients to run?
Time horizon reached?
Stop
Screening
Overall annual survival
Time counter advances
Update simulation data
ACEI – Angiotensin converting enzyme inhibitor
Microvascularcomplications
Macrovascularcomplications
Walczak J. , Pawlik D. , Jasińska A. , Garbacka M.. , Kędzior J. , Fundament T. , Malczak I. , Dardziński W. , Nogas G. , Skrzekowska-Baran I. , Czech M.Arcana Institute, Cracow, Poland, Novo Nordisk Pharma Poland, Warsaw, Poland
1 1 1 1 1 1 1 1 1 2 2
1 2
Insulin detemir PacketPublic selling
price (VAT
included) [PLN]
Reimbursement[PLN]
Patient’s co-payment
[PLN]
Reimbursementper
1 i.u. [PLN]
Levemir 5 wkł. 3ml 271,01 267,81 3,20 0,18
Type 1 and type 2 diabetespatients treated with IIT
Proportion of patients withepisodes of severe
hypoglycaemia *
Proportion of patientstreated with IIT,
receiving NPH insulinTarget population
65 800 0,089 95% 65 800 × 95% × 8,9% = about 5,6thousand patients
Total annual cost [PLN] IDet NPH
Type 1 diabetes
Insulin detemir/NPH 1 903,74 792,82
Short-/ rapid-acting insulin 828,42 592,85
Total 2 732,16 1 385,67
Type 2 diabetes (intensive insulin therapy)
Insulin detemir/NPH 2 662,87 1 005,92
Short-/ rapid-acting insulin 1 325,69 782,13
Total 3 988,56 1 788,05
Type 2 diabetes (insulin + oral antidiabetes drugs)
Insulin detemir/NPH 3 303,17 1 114,11
Oral antidiabetes drugs 327,38 327,38
Total 3 630,55 1 441,49
top related